StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

5-Methyl-3-isoxazolcarbonsäure-2-(phenylmethyl)hydrazid

Isocarboxazid

HCID 3759
Neue Reaktion
Drucken

Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen

GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
59-63-2
Standard-SMILES
Cc1cc(C(=O)NNCc2ccccc2)no1
InChIKey
XKFPYPQQHFEXRZ-UHFFFAOYSA-N
Summenformel
C12H13N3O2
Durchschnittliche Molmasse
231,25 g/mol
Monoisotopische Masse
231,10077667

Überblick

5-methyl-N'-(phenylmethyl)-3-isoxazolecarbohydrazide is a member of benzenes.

Namen und Bezeichner

Bevorzugter Name
Isocarboxazid
IUPAC
N'-benzyl-5-methyl-1,2-oxazole-3-carbohydrazide
Lokaler Name
5-Methyl-3-isoxazolcarbonsäure-2-(phenylmethyl)hydrazid
Englischer Name
ISOCARBOXAZID (200 MG)
Summenformel
C12H13N3O2
Molmasse
231.25

Namen und Synonyme

isocarboxazid59-63-2IsocarboxazideEnerzerMarplanIsocarbonazidIsocarbossazideN'-benzyl-5-methyl-1,2-oxazole-3-carbohydrazideIsocarboxazidaRo 5-0831Isocarboxazidum5-Methyl-3-isoxazolecarboxylic acid 2-benzylhydrazide
Weitere Namen anzeigen
1-Benzyl-2-(5-methyl-3-isoxazolylcarbonyl)hydrazineBmihMarplonBenazideMaraplanro5-0831
3-Isoxazolecarboxylic acid, 5-methyl-, 2-(phenylmethyl)hydrazideDTXSID4023171NSC-169893RO-5-0831NSC169893DTXCID00317134237V843T4-27-00-03999 (Beilstein Handbook Reference)

Datenbank-Bezeichner

CAS
59-63-2
PubChem CID
3759
DTXSID
DTXSID4023171
ChEMBL
CHEMBL1201168
ChEBI
CHEBI:93635

Eigenschaften

Berechnete StruktureigenschaftenWird ergänzt

XLogP
1,5
Polarare Oberfläche (TPSA)
67,2 Ų
H-Brücken-Donoren
2
H-Brücken-Akzeptoren
4
Frei drehbare Bindungen
4
Schwere Atome
17
Formalladung
0
Komplexität
254

Experimentelle und physikochemische Eigenschaften

Drugs · 2 Einträge

DEA NFLIS-Drug Category -> Stimulants

Pharmaceuticals -> Listed in ZINC15

LogP · 2 Einträge

2.4

1.49

Solubility · 2 Einträge

Very slightly soluble in hot water

2.24e-01 g/L

Human Drugs · 5 Einträge

Antidepressants -> Monoamine oxidase inhibitors (MAOI)

Breast Feeding; Lactation; Antidepressive Agents; Monoamine Oxidase Inhibitors;

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Pharmaceuticals

Boiling Point394.5ºC at 760 mmHg
Melting Point · 2 Einträge

105-106 °C

105 - 106 °C

Physical DescriptionSolid
Dissociation Constants10.4

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 4 Einträge

Danger

H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]

P264, P270, P301+P316, P321, P330, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 40 reports by companies from 2 notifications to the ECHA C&L Inventory.

Gefahrenhinweise

Regulatory Information3-Isoxazolecarboxylic acid, 5-methyl-, 2-(phenylmethyl)hydrazide: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.
Hazard Classes and CategoriesAcute Tox. 3 (100%)

Toxikologische Informationen

Treatment · 1 Eintrag

General supportive measures should be used, along with immediate gastric lavage or emetics. If the latter are given, the danger of aspiration must be borne in mind. An adequate airway should be maintained, with supplemental oxygen if necessary. The mechanism by which amine-oxidase inhibitors produce hypotension is not fully understood, but there is evidence that these agents block the vascular bed response. Thus it is suggested that plasma may be of value in the management of this hypotension. Administration of pressor amines such as levarterenol bitartrate may be of limited value (note that their effects may be potentiated by Isocarboxazid). Continue treatment for several days until homeostasis is restored. Liver function studies are recommended during the 4 to 6 weeks after recovery, as well as the time of overdosage.

Hepatotoxicity · 1 Eintrag

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 2 Einträge

N - Nervous system

QN - Nervous system

Protein Binding · 1 Eintrag

The pharmacokinetic profile of isocarboxazid have not been fully studied but it is suggested that its properties should be fairly similar to the ones of some analogs like phenelzine and tranylcypromine. These drugs present a very high protein binding percentage.

Pharmacodynamics · 1 Eintrag

In vivo and in vitro studies demonstrated isocarboxazid-driven inhibition of MAO in the brain, heart, and liver. The reduced MAO activity, caused by isocarboxazid, results in an increased concentration of serotonin, epinephrine, norepinephrine, and dopamine in storage sites throughout the central nervous system (CNS) and sympathetic nervous system. The increase of one or more monoamines is the basis for the antidepressant activity of MAO inhibitors like isocarboxazid.

Mechanism of Action · 1 Eintrag

Isocarboxazid works by irreversibly blocking the action of monoamine oxidases (MAO) in the nervous system. MAO subtypes A and B are involved in the metabolism of serotonin and catecholamine neurotransmitters such as epinephrine, norepinephrine, and dopamine. Isocarboxazid, as a nonselective MAO inhibitor, binds irreversibly to monoamine oxidase-A (MAO-A) and monoamine oxidase-B (MAO-B). Isocarboxacid, like other monoamine oxidase inhibitors, are unique psychopharmacological agents whose clinical effect is related to the direct action of the monoamine oxidases to transform them into reactive metabolites.

Biological Half-Life · 1 Eintrag

The pharmacokinetic profile of isocarboxazid have not been fully studied but it is suggested that its properties should be fairly similar to the ones of some analogs like phenelzine and tranylcypromine. The isocarboxazid half-life is of little interest as it is an irreversible monoamine oxidase inhibitor. These drugs present a very short half-life of 1.5-4 hours due to rapid hepatic metabolism.

Metabolism/Metabolites · 2 Einträge

Zugehörige Reaktionen

0
Reaktionsaufzeichnung erstellen
Noch keine zugehörigen Reaktionen

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
UNII
34237V843T
EC Number
200-438-4
Nikkaji
J4.794E
Collision Cross Section · 2 Einträge

150.7 Ų [M+H]+ [CCS Type: DT; Buffer gas: N2; Ionization: ESI+; Dataset: Antidepressants]

152.1 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]

Physikochemische Eigenschaften

Schmelzpunkt
98 · 98-1000C
Siedepunkt
373.33 °C · 373.33°C (rough estimate)
Dichte
1.206 · 1.206
Brechungsindex
1.529 · 1.5290 (estimate)
storage temp.
-20 °C · -20°C Freezer
Löslichkeit
Acetonitrile: Slightly Soluble; Chloroform: Slightly Soluble
Aggregatzustand
A solid
pka
10.4 · pKa 10.4 (Uncertain)
Farbe
White to off-white
Wasserlöslichkeit
0.8 g/L · 0.8g/L(25 ºC)
InChI
1S/C12H13N3O2/c1-9-7-11(15-17-9)12(16)14-13-8-10-5-3-2-4-6-10/h2-7,13H,8H2,1H3,(H,14,16)
InChIKey
XKFPYPQQHFEXRZ-UHFFFAOYSA-N
SMILES
Cc1cc(no1)C(=O)NNCc2ccccc2

Isocarboxazid, like most monoamine oxidase (MAO) inhibitors, can cause transient serum aminotransferase elevations in a proportion of patients. These elevations are usually mild, asymptomatic and self-limited and do not require dose modification. MAO inhibitors have been associated with rare cases of acute, clinically apparent liver injury but isocarboxazid has not specifically been implicated. The time to clinical onset of liver injury due to MAO inhibitors is typically 1 to 4 months after starting and the usual pattern of serum enzyme elevations is hepatocellular, although cholestatic injury has also been described. Immunoallergic features (rash, fever, eosinophilia) are uncommon as is autoantibody formation. Isocarboxazid has not been directly implicated in cases of drug-induced liver injury but it has had limited clinical use.

Exposure RoutesWell absorbed from the gastrointestinal tract.
Toxicity Summary · 1 Eintrag

Isocarboxazid works by irreversibly blocking the action of a chemical substance known as monoamine oxidase (MAO) in the nervous system. MAO subtypes A and B are involved in the metabolism of serotonin and catecholamine neurotransmitters such as epinephrine, norepinephrine, and dopamine. Isocarboxazid, as a nonselective MAO inhibitor, binds irreversibly to monoamine oxidase–A (MAO-A) and monoamine oxidase–B (MAO-B). The reduced MAO activity results in an increased concentration of these neurotransmitters in storage sites throughout the central nervous system (CNS) and sympathetic nervous system. This increased availability of one or more monoamines is the basis for the antidepressant activity of MAO inhibitors.

Signs and Symptoms · 1 Eintrag

Signs of overdose include severe anxiety, confusion, convulsions, cool clammy skin, severe dizziness, severe drowsiness, fast and irregular pulse, fever, hallucinations, severe headache, high or low blood pressure, hyperactive reflexes, muscle stiffness, respiratory depression or failure, slowed reflexes, sweating, severe trouble in sleeping, and unusual irritability.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 6 Einträge

Drug Induced Liver Injury Rank (DILIrank 2.0)

Isocarboxazid

Ambiguous-DILI-concern

5

Warnings & precautions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Sicherheitsdaten

wgk
WGK 3
ridadr
3249
hs_code
2934990002
hazard_class
6.1(b)
packing_group
III
Speicherklasse
6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
Hazard Classifications
Acute Tox. 3 Oral

The pharmacokinetic profile of isocarboxazid have not been fully studied but it is suggested that its properties should be fairly similar to the ones of some analogs like phenelzine and tranylcypromine. These drugs are rapidly metabolized by acetylation in the liver. As part of the metabolism, hippuric acid is a major metabolite.

Hepatic and rapid (by oxidation).

FDA Pharmacological Classification · 6 Einträge

34237V843T

ISOCARBOXAZID

Established Pharmacologic Class [EPC] - Monoamine Oxidase Inhibitor

Mechanisms of Action [MoA] - Monoamine Oxidase Inhibitors

Isocarboxazid is a Monoamine Oxidase Inhibitor. The mechanism of action of isocarboxazid is as a Monoamine Oxidase Inhibitor.

ISOCARBOXAZID

MeSH Pharmacological Classification · 2 Einträge

Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems.

A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p414)

Absorption, Distribution and Excretion · 2 Einträge

The pharmacokinetic profile of isocarboxazid have not been fully studied but it is suggested that its properties should be fairly similar to the ones of some analogs like phenelzine and tranylcypromine. These drugs are readily absorbed by the GI tract, present a low bioavailability and reach peak concentrations in 1-2 hours.

Most of the eliminated dose is found in the urine, accounting for the 42.5% of the administered dose after 24 hours. From this amount, 75% of the renally eliminated drug is in the form of hippuric acid. Another section of the eliminated dose is observed through the intestinal tract and it accounts for 22% of the administered dose after 24 hours.

Cellular LocationsCytoplasm

Verwendung und Herstellung

UsesMay be used to treat major depressive disorder.
Use ClassificationPharmaceuticals

Anwendungen

VerwendenMonoamine oxidase inhibitor. Antidepressant

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

Lithium Aluminum HydrideBenzaldehyd5-Methyl-3-isoxazolecarboxylic Acid HydrazideBenzylhydrazindihydrochlorid5-Methyl-3-isoxazolecarboxylic Acid BenzylidenehydrazideMethyl-5-methylisoxazol-3-carboxylatBenzylhydrazine